etodolac has been researched along with Arthritis, Rheumatoid in 46 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "9 years) with rheumatoid arthritis (RA) (10 with normal renal function and 3 with moderate renal insufficiency) participated in a 5-day study to assess the effects of etodolac on renal function and the necessity of dose adjustment." | 9.09 | [Investigation of plasma levels of etodolac and urine PGE2 in patients with rheumatoid arthritis]. ( Aoki, A; Chiba, J; Hagiya, N; Ishigatsubo, Y; Kawai, T; Matsunaga, K; Motoji, K; Nagaoka, S; Nakamura, M; Senuma, A; Tani, K; Yawata, M, 1999) |
| "We compared the longterm efficacy and safety of 2 dosages of etodolac with that of ibuprofen in the treatment of active rheumatoid arthritis (RA)." | 9.08 | Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. ( Neustadt, DH, 1997) |
| "The efficacy and safety of etodolac and piroxicam in patients with active rheumatoid arthritis were compared." | 9.08 | Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group. ( Lightfoot, R, 1997) |
| "A study was carried out to compare the efficacy and tolerability of etodolac and piroxicam in patients with rheumatoid arthritis." | 9.07 | Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis. ( Schattenkirchner, M, 1991) |
| "MTX (10 mg) was administered intramuscularly in the absence and presence of steady state levels of etodolac in 19 patients with rheumatoid arthritis." | 9.07 | Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ( Alric, R; Anaya, JM; Bologna, C; Bressolle, F; Cocciglio, M; Dropsy, R; Fabre, D; Sany, J, 1994) |
| "Etodolac was compared with aspirin and placebo for efficacy and safety, and a minimum effective dose was established in 264 patients with adult-onset, active rheumatoid arthritis." | 9.06 | Minimum effective dose of etodolac for the treatment of rheumatoid arthritis. ( Epstein, C; Jacob, G; Kennedy, J; Messina, M; Mullane, J; Sanda, M, 1986) |
| "A 14-day double-blind clinical study was conducted on 16 patients with clinically active rheumatoid arthritis to compare the effects of etodolac (600 mg daily) and diclofenac (150 mg daily)." | 9.06 | Etodolac versus diclofenac: double-blind cross-over study in rheumatoid arthritis. ( Bazzichi, L; Ciompi, ML; Marotta, G; Puccetti, L; Remorini, E, 1989) |
| "The therapeutic efficacy and upper gastrointestinal side effects of a twice daily dose of 300 mg etodolac and 500 mg naproxen were compared in 30 hospital out-patients with active rheumatoid arthritis." | 9.06 | Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. ( McLaughlin, S; Russell, RI; Sturrock, RD; Taha, AS, 1989) |
| "Etodolac, a nonsteroidal anti-inflammatory drug (NSAID) of the pyranocarboxylic acid family, has been tested in international clinical trials as a therapy for rheumatoid arthritis (RA)." | 9.06 | International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy. ( Briancon, D, 1989) |
| "The synthesis of gastric and duodenal mucosal prostaglandin E2, prostaglandin I2, and thromboxane B2 during a 60 minute incubation of biopsy specimens, the degree of endoscopic and histological damage, and the anti-inflammatory response were all studied after a four week, double blind study of therapeutic doses of two non-steroidal anti-inflammatory drugs, naproxen and etodolac, received by 27 patients with active rheumatoid arthritis (13 receiving naproxen, 14 etodolac)." | 9.06 | Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis. ( Holland, PJ; Kelly, RW; McLaughlin, S; Russell, RI; Sturrock, RD; Taha, AS, 1990) |
| "Etodolac and naproxen were compared using a randomized double-blind, crossover method in 39 hospital out-patients with rheumatoid arthritis." | 9.06 | Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study. ( Waltham-Weeks, CD, 1987) |
| "Etodolac, aspirin, and placebo were evaluated for efficacy and safety in 20 patients with adult-onset active rheumatoid arthritis who entered a 12-week, double-blind, parallel-group study divided into drug titration and maintenance periods and preceded by a two-week washout period." | 9.05 | Twelve-week study of etodolac, aspirin, and placebo in patients with rheumatoid arthritis. ( Concepción, R; del Toro, RA, 1983) |
| "Etodolac, aspirin, and placebo were evaluated for efficacy and safety in 18 patients with adult-onset, active rheumatoid arthritis." | 9.05 | Etodolac, aspirin, and placebo in patients with rheumatoid arthritis: a 12-week study. ( Edwards, W, 1983) |
| "The effectiveness of etodolac in the treatment of patients with osteoarthritis (OA) and with rheumatoid arthritis (RA) has been well documented in controlled clinical trials." | 8.79 | Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis. ( Veys, EM, 1994) |
| "Short and longterm safety and efficacy of etodolac in a wide range of dosages in patients with rheumatoid arthritis (RA) are summarized." | 8.79 | Low dose etodolac in rheumatoid arthritis: a review of early studies. ( Spencer-Green, G, 1997) |
| "Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) effective in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, and in the alleviation of postoperative pain." | 8.78 | Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. ( Balfour, JA; Buckley, MM, 1991) |
| "A meta-analysis was done with the data from two studies that provided the first efficacy and safety results for the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis (RA)." | 8.78 | Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis. ( Porzio, F, 1993) |
| " The pharmacokinetic study in human volunteers showed that the selected etodolac-loaded cubosomes enhanced the bioavailability of etodolac as compared to the oral capsules (266." | 5.46 | Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies. ( Kamel, AO; Mahmoud, AA; Salah, S, 2017) |
| "This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac." | 5.34 | Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. ( Aoyama, M; Deji, N; Kashiwagi, A; Kikuchi, K; Nishio, Y; Sakaguchi, M; Sugimoto, T; Uzu, T, 2007) |
| "9 years) with rheumatoid arthritis (RA) (10 with normal renal function and 3 with moderate renal insufficiency) participated in a 5-day study to assess the effects of etodolac on renal function and the necessity of dose adjustment." | 5.09 | [Investigation of plasma levels of etodolac and urine PGE2 in patients with rheumatoid arthritis]. ( Aoki, A; Chiba, J; Hagiya, N; Ishigatsubo, Y; Kawai, T; Matsunaga, K; Motoji, K; Nagaoka, S; Nakamura, M; Senuma, A; Tani, K; Yawata, M, 1999) |
| "The efficacy and safety of etodolac and piroxicam in patients with active rheumatoid arthritis were compared." | 5.08 | Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group. ( Lightfoot, R, 1997) |
| "We compared the longterm efficacy and safety of 2 dosages of etodolac with that of ibuprofen in the treatment of active rheumatoid arthritis (RA)." | 5.08 | Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. ( Neustadt, DH, 1997) |
| "MTX (10 mg) was administered intramuscularly in the absence and presence of steady state levels of etodolac in 19 patients with rheumatoid arthritis." | 5.07 | Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ( Alric, R; Anaya, JM; Bologna, C; Bressolle, F; Cocciglio, M; Dropsy, R; Fabre, D; Sany, J, 1994) |
| "A study was carried out to compare the efficacy and tolerability of etodolac and piroxicam in patients with rheumatoid arthritis." | 5.07 | Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis. ( Schattenkirchner, M, 1991) |
| "The safety profile of a new sustained-release (SR) form of etodolac was evaluated in 539 young and elderly patients with osteoarthritis or rheumatoid arthritis." | 5.07 | The safety profile of sustained-release etodolac. ( Schattenkirchner, M, 1993) |
| "The synthesis of gastric and duodenal mucosal prostaglandin E2, prostaglandin I2, and thromboxane B2 during a 60 minute incubation of biopsy specimens, the degree of endoscopic and histological damage, and the anti-inflammatory response were all studied after a four week, double blind study of therapeutic doses of two non-steroidal anti-inflammatory drugs, naproxen and etodolac, received by 27 patients with active rheumatoid arthritis (13 receiving naproxen, 14 etodolac)." | 5.06 | Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis. ( Holland, PJ; Kelly, RW; McLaughlin, S; Russell, RI; Sturrock, RD; Taha, AS, 1990) |
| "Etodolac was compared with aspirin and placebo for efficacy and safety, and a minimum effective dose was established in 264 patients with adult-onset, active rheumatoid arthritis." | 5.06 | Minimum effective dose of etodolac for the treatment of rheumatoid arthritis. ( Epstein, C; Jacob, G; Kennedy, J; Messina, M; Mullane, J; Sanda, M, 1986) |
| "Etodolac, a nonsteroidal anti-inflammatory drug (NSAID) of the pyranocarboxylic acid family, has been tested in international clinical trials as a therapy for rheumatoid arthritis (RA)." | 5.06 | International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy. ( Briancon, D, 1989) |
| "Etodolac has been shown to have a favorable safety profile in short-term and long-term studies in both osteoarthritis (OA) and rheumatoid arthritis (RA)." | 5.06 | Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins. ( Russell, RI, 1990) |
| "A 14-day double-blind clinical study was conducted on 16 patients with clinically active rheumatoid arthritis to compare the effects of etodolac (600 mg daily) and diclofenac (150 mg daily)." | 5.06 | Etodolac versus diclofenac: double-blind cross-over study in rheumatoid arthritis. ( Bazzichi, L; Ciompi, ML; Marotta, G; Puccetti, L; Remorini, E, 1989) |
| "The therapeutic efficacy and upper gastrointestinal side effects of a twice daily dose of 300 mg etodolac and 500 mg naproxen were compared in 30 hospital out-patients with active rheumatoid arthritis." | 5.06 | Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. ( McLaughlin, S; Russell, RI; Sturrock, RD; Taha, AS, 1989) |
| " In this study, the effect on gastrointestinal blood loss of high-dose etodolac, 300 and 500 mg bid, versus piroxicam at its normal therapeutic dose of 20 mg qd, was investigated by the 51Cr method in 23 men with osteo- or rheumatoid arthritis." | 5.06 | Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam. ( Garg, DC; Jallad, NS; Mullane, JF; Perdomo, CS; Salom, IL; Sanda, M; Weidler, DJ, 1986) |
| "Etodolac and naproxen were compared using a randomized double-blind, crossover method in 39 hospital out-patients with rheumatoid arthritis." | 5.06 | Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study. ( Waltham-Weeks, CD, 1987) |
| "Etodolac, aspirin, and placebo were evaluated for efficacy and safety in 20 patients with adult-onset active rheumatoid arthritis who entered a 12-week, double-blind, parallel-group study divided into drug titration and maintenance periods and preceded by a two-week washout period." | 5.05 | Twelve-week study of etodolac, aspirin, and placebo in patients with rheumatoid arthritis. ( Concepción, R; del Toro, RA, 1983) |
| "Etodolac, aspirin, and placebo were evaluated for efficacy and safety in 18 patients with adult-onset, active rheumatoid arthritis." | 5.05 | Etodolac, aspirin, and placebo in patients with rheumatoid arthritis: a 12-week study. ( Edwards, W, 1983) |
| "The effectiveness of etodolac in the treatment of patients with osteoarthritis (OA) and with rheumatoid arthritis (RA) has been well documented in controlled clinical trials." | 4.79 | Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis. ( Veys, EM, 1994) |
| "Short and longterm safety and efficacy of etodolac in a wide range of dosages in patients with rheumatoid arthritis (RA) are summarized." | 4.79 | Low dose etodolac in rheumatoid arthritis: a review of early studies. ( Spencer-Green, G, 1997) |
| "Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) effective in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, and in the alleviation of postoperative pain." | 4.78 | Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. ( Balfour, JA; Buckley, MM, 1991) |
| "A meta-analysis was done with the data from two studies that provided the first efficacy and safety results for the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis (RA)." | 4.78 | Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis. ( Porzio, F, 1993) |
| "Etodolac has previously been reported to have an excellent safety profile." | 3.76 | A global safety evaluation of etodolac. ( Karbowski, A, 1989) |
| " Data from patients 65 years and older with osteoarthritis or rheumatoid arthritis show that etodolac is as well tolerated in elderly as in younger patients." | 3.69 | Safety profile of etodolac in the elderly population. ( Bacon, PA, 1994) |
| "Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID) that has shown a favorable safety profile in clinical trials in osteoarthritis (OA) and rheumatoid arthritis (RA)." | 3.68 | Global safety of etodolac: reports from worldwide postmarketing surveillance studies. ( Serni, U, 1990) |
| " A total of 1276 adverse reactions (AR) were reported during the study, and fewer than half of these were related to study treatment." | 2.67 | Large-scale open trials with etodolac (Lodine) in France: an assessment of safety. ( Benhamou, CL, 1990) |
| "Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID) with potent analgesic and antiarthritic properties." | 2.67 | An overview of the efficacy of etodolac in arthritic disorders. ( Bacon, PA, 1990) |
| " Although ketorolac, which is now available in oral form, is an effective analgesic, its long-term use is limited by a high incidence of gastrointestinal toxicity." | 2.39 | A review of selected newer nonsteroidal anti-inflammatory drugs. ( Amadio, P; Cummings, DM, 1994) |
| "Etodolac has also been shown to be very well tolerated." | 2.38 | A review of the antiarthritic efficacy and safety of etodolac. ( Zvaifler, N, 1989) |
| "Etodolac is a new non-steroidal agent (NSAID) with anti-inflammatory and analgesic activity." | 2.37 | Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use. ( Brogden, RN; Lynch, S, 1986) |
| " The pharmacokinetic study in human volunteers showed that the selected etodolac-loaded cubosomes enhanced the bioavailability of etodolac as compared to the oral capsules (266." | 1.46 | Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies. ( Kamel, AO; Mahmoud, AA; Salah, S, 2017) |
| "This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac." | 1.34 | Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. ( Aoyama, M; Deji, N; Kashiwagi, A; Kikuchi, K; Nishio, Y; Sakaguchi, M; Sugimoto, T; Uzu, T, 2007) |
| " No differences in the half-life of etodolac elimination were noted." | 1.27 | The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis. ( Furst, D; Furst, J; Hicks, DR; Kraml, M; McKean, M; Panagides, J, 1988) |
| "Etodolac-low dose was significantly more effective than placebo in nine of ten clinical assessments and in all ten at high dose." | 1.26 | Comparative efficacy of etodolac and placebo in rheumatoid arthritic patients. ( Joubert, L; Placchi, M; Vetter, G, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (41.30) | 18.7374 |
| 1990's | 21 (45.65) | 18.2507 |
| 2000's | 4 (8.70) | 29.6817 |
| 2010's | 2 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asselin, AA | 1 |
| Humber, LG | 2 |
| Dobson, TA | 1 |
| Komlossy, J | 1 |
| Martel, RR | 1 |
| Demerson, CA | 1 |
| Philipp, AH | 1 |
| Salah, S | 1 |
| Mahmoud, AA | 1 |
| Kamel, AO | 1 |
| Mehta, P | 1 |
| Lukacs, M | 1 |
| Abraham, SM | 1 |
| Paulus, HE | 2 |
| Di Primeo, D | 2 |
| Sharp, JT | 2 |
| Genant, HK | 2 |
| Weissman, BN | 2 |
| Weisman, MH | 1 |
| Sanda, M | 5 |
| Tanaka, H | 1 |
| Abe, T | 1 |
| Nishimura, S | 1 |
| Sakai, H | 1 |
| Kimura, H | 1 |
| Oki, M | 1 |
| Nojima, M | 1 |
| Taga, M | 1 |
| Matsumoto, S | 1 |
| Takahashi, H | 1 |
| Imai, K | 1 |
| Sugimoto, T | 1 |
| Aoyama, M | 1 |
| Kikuchi, K | 1 |
| Sakaguchi, M | 1 |
| Deji, N | 1 |
| Uzu, T | 1 |
| Nishio, Y | 1 |
| Kashiwagi, A | 1 |
| Vetter, G | 1 |
| Placchi, M | 1 |
| Joubert, L | 1 |
| del Toro, RA | 1 |
| Concepción, R | 1 |
| Edwards, W | 1 |
| Bacon, PA | 2 |
| Veys, EM | 1 |
| Cummings, DM | 1 |
| Amadio, P | 1 |
| Anaya, JM | 1 |
| Fabre, D | 1 |
| Bressolle, F | 1 |
| Bologna, C | 1 |
| Alric, R | 1 |
| Cocciglio, M | 1 |
| Dropsy, R | 1 |
| Sany, J | 1 |
| Dreiser, RL | 1 |
| Porzio, F | 1 |
| Schattenkirchner, M | 2 |
| Lonauer, G | 1 |
| Tisscher, JR | 1 |
| Lim, HG | 1 |
| Bijlsma, JW | 1 |
| Spencer-Green, G | 1 |
| Lightfoot, R | 1 |
| Neustadt, DH | 1 |
| Matsunaga, K | 1 |
| Yawata, M | 1 |
| Hagiya, N | 1 |
| Tani, K | 1 |
| Kawai, T | 1 |
| Nagaoka, S | 1 |
| Aoki, A | 1 |
| Nakamura, M | 1 |
| Senuma, A | 1 |
| Motoji, K | 1 |
| Chiba, J | 1 |
| Ishigatsubo, Y | 1 |
| Lynch, JM | 1 |
| Schwartz, BA | 1 |
| Balfour, JA | 1 |
| Buckley, MM | 1 |
| Bianchi Porro, G | 1 |
| Caruso, I | 1 |
| Petrillo, M | 1 |
| Montrone, F | 1 |
| Ardizzone, S | 1 |
| Taha, AS | 2 |
| McLaughlin, S | 2 |
| Holland, PJ | 1 |
| Kelly, RW | 1 |
| Sturrock, RD | 2 |
| Russell, RI | 3 |
| Serni, U | 1 |
| Benhamou, CL | 1 |
| Puccetti, L | 2 |
| Soletti, A | 1 |
| Petrini, G | 1 |
| Remorini, E | 2 |
| Zuccotti, M | 1 |
| Bazzichi, L | 2 |
| Ciompi, ML | 2 |
| Zvaifler, N | 1 |
| Briancon, D | 1 |
| Karbowski, A | 1 |
| Marotta, G | 1 |
| Gospodinoff, A | 1 |
| Fiore, L | 1 |
| Dardano, B | 1 |
| Fiore, D | 1 |
| Scapato, P | 1 |
| Jacob, G | 1 |
| Messina, M | 1 |
| Kennedy, J | 1 |
| Epstein, C | 2 |
| Mullane, J | 1 |
| Shand, DG | 1 |
| Kinberg-Calhoun, J | 1 |
| Mullane, JF | 2 |
| Lynch, S | 1 |
| Brogden, RN | 1 |
| Jallad, NS | 1 |
| Salom, IL | 1 |
| Perdomo, CS | 1 |
| Garg, DC | 1 |
| Weidler, DJ | 1 |
| Waltham-Weeks, CD | 1 |
| Wooley, PH | 1 |
| Whalen, JD | 1 |
| Zimmerman, JL | 1 |
| Champion, TM | 1 |
| Kraml, M | 1 |
| Hicks, DR | 1 |
| McKean, M | 1 |
| Panagides, J | 1 |
| Furst, D | 1 |
| Furst, J | 1 |
9 reviews available for etodolac and Arthritis, Rheumatoid
| Article | Year |
|---|---|
[A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy].
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, C | 2004 |
Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Etodolac; | 1994 |
A review of selected newer nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Trials as Topic; | 1994 |
Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Delayed-Action Prepa | 1993 |
Low dose etodolac in rheumatoid arthritis: a review of early studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Humans | 1997 |
Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Humans; Indoleace | 1991 |
A review of the antiarthritic efficacy and safety of etodolac.
Topics: Activities of Daily Living; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Binding, | 1989 |
A global safety evaluation of etodolac.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1989 |
Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use.
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Etodolac; Humans; | 1986 |
27 trials available for etodolac and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2004 |
Twelve-week study of etodolac, aspirin, and placebo in patients with rheumatoid arthritis.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as | 1983 |
Etodolac, aspirin, and placebo in patients with rheumatoid arthritis: a 12-week study.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as | 1983 |
Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Proteins; Drug Interactions; Etodolac; Female; Humans; Mal | 1994 |
A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Dose-Response Relationship, Drug; D | 1993 |
The safety profile of sustained-release etodolac.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Dose-Response Relation | 1993 |
Double-blind comparison of etodolac and diclofenac in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Etodolac; Female; Humans; Male; Middle A | 1993 |
Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Respon | 1997 |
Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Double-B | 1997 |
[Investigation of plasma levels of etodolac and urine PGE2 in patients with rheumatoid arthritis].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dinoproston | 1999 |
Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Arthrography; Disease Progression; Dose-Response Rel | 2000 |
A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Etodolac; Femal | 1991 |
Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Et | 1991 |
Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1990 |
An overview of the efficacy of etodolac in arthritic disorders.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; | 1990 |
Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dinoproston | 1990 |
Large-scale open trials with etodolac (Lodine) in France: an assessment of safety.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Rel | 1990 |
Effectiveness and safety of etodolac in treatment of rheumatoid arthritis: a multicentre two-months' open study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Female; Human | 1990 |
Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Dr | 1989 |
International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; | 1989 |
A global safety evaluation of etodolac.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1989 |
Etodolac versus diclofenac: double-blind cross-over study in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Sedimentation; Clinical | 1989 |
Minimum effective dose of etodolac for the treatment of rheumatoid arthritis.
Topics: Acetates; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rhe | 1986 |
The effect of etodolac administration on renal function in patients with arthritis.
Topics: Acetates; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Blood Urea | 1986 |
Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response | 1986 |
Etodolac--a new NSAID for rheumatoid arthritis.
Topics: Acetates; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Double-Blind Method; Etodolac; H | 1987 |
Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind | 1987 |
11 other studies available for etodolac and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Cycloalkanoindoles. 1. Syntheses and antiinflammatory actions of some acidic tetrahydrocarbazoles, cyclopentindoles, and cycloheptindoles.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Carbazoles; Cycloheptanes; Cyclopentanes; | 1976 |
Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acids.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Carrageenan; Freund's Adjuvant; Indoleacet | 1976 |
Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies.
Topics: Administration, Cutaneous; Animals; Arthritis, Rheumatoid; Drug Liberation; Etodolac; Humans; Partic | 2017 |
Normal in the blood, abnormal in the urine.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Bilirubi | 2012 |
Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biopsy, Needle; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Follow-Up Stud | 2007 |
Comparative efficacy of etodolac and placebo in rheumatoid arthritic patients.
Topics: Acetates; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relati | 1982 |
Safety profile of etodolac in the elderly population.
Topics: Age Factors; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Delayed-Action Preparations; Dic | 1994 |
Global safety of etodolac: reports from worldwide postmarketing surveillance studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 1990 |
[Open clinical study on the efficacy and tolerance of acemetacin in rheumatoid arthritis and osteoarthrosis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Female; Human | 1989 |
The effect of etodolac on type II collagen-induced arthritis in mice.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Collagen; Etodola | 1987 |
The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Fem | 1988 |